Sunshine Biopharma, Inc. has contracted Beta Pharma Canada, Inc. to manufacture an initial batch of its Adva-27a cancer drug and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.
 
Beta Pharma Canada, Inc., headquartered in Montreal, is an affiliate of Beta Pharma, Inc. with offices and facilities in Connecticut and Shanghai. Adva-27a is Sunshine's lead anti-cancer compound, which has been proven effective in killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
 
"We are delighted to be working with Beta Pharma Canada with excellent in-house synthesis capability and can amass additional Resources through its corporate affiliations," said Dr. Steve N. Slilaty, Sunshine's president and chief executive officer. "We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month.”